In FY2015 we have substantially advanced the goals and objectives for the ClinSeq clinical and behavioral project by performing the following ongoing substudies. Incidental findings. The topic of incidental findings has exploded onto the clinical and research agenda, to no small extent facilitated by the ClinSeq(c) study. In the prior periods, we piloted incidental findings by identifying cancer susceptibility variants (Johnston et al, 2012), cardiomyopathy and dysrhythmia variants (Ng et al, 2013) and malignant hyperthermia (Gonsalves et al, 2013). We have extending this into a broader project to explore all null variants (novel and known) in genes known to cause human disease in an autosomal dominant pattern and correlating this with phenotype. This was published in Am J Hum Genet this year. Randomized controlled trial of return of results As sequencing technology is new, it is important to understand how the medical system can take up this technology. As an important foundation for understanding many related questions, we have developed an extensive survey of baseline attitudes towards this sequencing technology. This survey has been completed, analyzed, and a draft publication will be submitted this fall. Our major effort in this domain is that we have initiated a large (n=400), controlled experiment with experimental arms that vary the mode of return of results to compare the classical model of direct clinician interaction with a new mode of web-based results return. This experiment will be key to discovering efficient modes of return of results. We are currently accruing 10 participants per week for this study. We are also exploring participant reactions to variants of uncertain clinical significance. This is a major challenge in genomics and we have designed a trial where we will return variants of unknown significance either above or below the 50% threshold of likelihood of pathogenicity to gauge participant reactions to such variants, and measure their intentions to implement medical care based on these results.

Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Human Genome Research
Department
Type
DUNS #
City
State
Country
Zip Code
Amendola, Laura M; Berg, Jonathan S; Horowitz, Carol R et al. (2018) The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations. Am J Hum Genet 103:319-327
Miller, Ilana M; Lewis, Katie L; Lawal, Tokunbor A et al. (2018) Health behaviors among unaffected participants following receipt of variants of uncertain significance in cardiomyopathy-associated genes. Genet Med :
Tavtigian, Sean V; Greenblatt, Marc S; Harrison, Steven M et al. (2018) Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med 20:1054-1060
Christensen, Kurt D; Bernhardt, Barbara A; Jarvik, Gail P et al. (2018) Anticipated responses of early adopter genetic specialists and nongenetic specialists to unsolicited genomic secondary findings. Genet Med 20:1186-1195
Lewis, Katie L; Umstead, Kendall L; Johnston, Jennifer J et al. (2018) Outcomes of Counseling after Education about Carrier Results: A Randomized Controlled Trial. Am J Hum Genet 102:540-546
Turbitt, Erin; Roberts, Megan C; Ferrer, Rebecca A et al. (2018) Intentions to share exome sequencing results with family members: exploring spousal beliefs and attitudes. Eur J Hum Genet 26:735-739
Biesecker, Leslie G (2018) Genomic screening for monogenic forms of diabetes. BMC Med 16:25
Biesecker, Leslie G (2018) Secondary findings in exome slices, virtual panels, and anticipatory sequencing. Genet Med :
Biesecker, B B; Woolford, S W; Klein, W M P et al. (2018) Correction to: PUGS: A novel scale to assess perceptions of uncertainties in genome sequencing. Clin Genet 93:1119
Porter, Kathryn M; Kauffman, Tia L; Koenig, Barbara A et al. (2018) Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience. Mol Genet Genomic Med 6:898-909

Showing the most recent 10 out of 61 publications